Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
520 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
Rank Status Study
21 Not yet recruiting GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
Interventions: Drug: GO-203-2C;   Drug: Bortezomib
22 Not yet recruiting A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
Condition: Multiple Myeloma
23 Recruiting Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
24 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
25 Recruiting Pembrolizumab for Smoldering Multiple Myeloma (SMM)
Condition: Smoldering Multiple Myeloma
Intervention: Drug: Pembrolizumab
26 Recruiting High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BeEAM
27 Not yet recruiting Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Condition: High Risk Smoldering Multiple Myeloma
Intervention: Drug: Ibrutinib
28 Recruiting A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: AMG 224
29 Recruiting A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities
Conditions: Solid Tumors;   Multiple Myeloma
Intervention: Drug: TAS-120
30 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
Condition: Multiple Myeloma
Intervention: Biological: TAA-specific CTLs
32 Recruiting A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Condition: Smoldering Multiple Myeloma (SMM)
Intervention: Drug: daratumumab
33 Unknown  Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
34 Recruiting An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Other: No Intervention
35 Recruiting Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Conditions: Multiple Myeloma;   Renal Impairment
Interventions: Drug: 4 mg Oral POM + 40 mg Oral DEX;   Drug: 2 mg Oral POM + 40 mg Oral DEX
36 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
37 Recruiting Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
Condition: Multiple Myeloma
38 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: ABT-199;   Drug: Dexamethasone
39 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
40 Recruiting Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
Condition: Multiple Myeloma in Older Patients
Intervention: Other: Vulnerability and therapeutic changes in older patients with multiple myeloma.

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years